Enzo Biochem (ENZ) Q3 2024 earnings summary

Executive summary

• Revenue for the quarter ended April 30, 2024 was $8.0 million, up 7% year-over-year, driven by growth in Europe and Asia Pacific, and four consecutive quarters of growth in the Life Science division.

• Net loss from continuing operations for the quarter was $2.1 million, a significant improvement from $7.9 million in the prior year quarter.

• Gross margin improved to 47% in Q3, up 700 basis points year-over-year, reflecting favorable product mix and cost containment.

• The company completed the sale of its Clinical Labs business to Labcorp in July 2023, classifying all related results as discontinued operations.

• Q3 operating income for Life Science was $0.3 million, reversing a $1.0 million loss last year.

Financial highlights

• Nine-month revenue was $24.4 million, up 10% year-over-year, with growth across all major geographic markets.

• Q3 gross profit: $3.7 million (47% margin); nine-month gross profit: $11.4 million (47% margin).

• Operating loss for the nine months was $9.7 million, a 45% improvement from $17.5 million in the prior year period.

• Cash and cash equivalents at April 30, 2024 were $57.2 million, down from $83.4 million at July 31, 2023, mainly due to net loss and paydown of liabilities.

• Working capital stood at $54.1 million as of April 30, 2024.

Outlook and guidance

• Management expects continued revenue growth and margin expansion, supported by a focused Life Science tools strategy and enhanced digital presence.

• Management believes current working capital is sufficient to meet operating requirements for the next twelve months.

• No material trends or uncertainties are expected to negatively impact liquidity or sales in the near term.